Galectin-3 as a marker and potential therapeutic target in breast cancer.
Galectin-3 has a relatively high level of expression in triple-negative breast cancers and is a potential marker for this disease. However, the clinical and prognostic implications of galectin-3 expression in breast cancer remain unclear. We examined mastectomy specimens from 1086 breast cancer case...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4177814?pdf=render |
| _version_ | 1818258790504464384 |
|---|---|
| author | Hao Zhang Minna Luo Xi Liang Dan Wang Xin Gu Chao Duan Huizi Gu Guanglei Chen Xinhan Zhao Zuowei Zhao Caigang Liu |
| author_facet | Hao Zhang Minna Luo Xi Liang Dan Wang Xin Gu Chao Duan Huizi Gu Guanglei Chen Xinhan Zhao Zuowei Zhao Caigang Liu |
| author_sort | Hao Zhang |
| collection | DOAJ |
| description | Galectin-3 has a relatively high level of expression in triple-negative breast cancers and is a potential marker for this disease. However, the clinical and prognostic implications of galectin-3 expression in breast cancer remain unclear. We examined mastectomy specimens from 1086 breast cancer cases and matching, adjacent non-cancerous tissues using immunohistochemistry. Overall, triple-negative breast cancers expressed galectin-3 more strongly than did other breast cancers types (63.59% vs 21.36%, P = 0.001). Galectin-3 expression was not found to be an independent prognostic factor for breast cancer by Cox regression analysis, but was associated with chemotherapeutic resistance. Apoptosis was only weakly induced by arsenic trioxide (ATO) treatment in galectin-3-positive breast cancer cells (MDA-MB-231 and MCF-7), although ATO treatment up-regulated galectin-3 expression. Knockdown of galectin-3 in MDA-MB-231 cells sensitized them to killing by ATO. These findings support a possible role for galectin-3 as a marker for triple-negative breast cancer progression and as a therapeutic target in combination with ATO treatment, although the mechanisms that underlie this synergy require further investigation. |
| first_indexed | 2024-12-12T18:05:09Z |
| format | Article |
| id | doaj.art-331de769c821402ca3e302226ba75389 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-12T18:05:09Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-331de769c821402ca3e302226ba753892022-12-22T00:16:31ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0199e10348210.1371/journal.pone.0103482Galectin-3 as a marker and potential therapeutic target in breast cancer.Hao ZhangMinna LuoXi LiangDan WangXin GuChao DuanHuizi GuGuanglei ChenXinhan ZhaoZuowei ZhaoCaigang LiuGalectin-3 has a relatively high level of expression in triple-negative breast cancers and is a potential marker for this disease. However, the clinical and prognostic implications of galectin-3 expression in breast cancer remain unclear. We examined mastectomy specimens from 1086 breast cancer cases and matching, adjacent non-cancerous tissues using immunohistochemistry. Overall, triple-negative breast cancers expressed galectin-3 more strongly than did other breast cancers types (63.59% vs 21.36%, P = 0.001). Galectin-3 expression was not found to be an independent prognostic factor for breast cancer by Cox regression analysis, but was associated with chemotherapeutic resistance. Apoptosis was only weakly induced by arsenic trioxide (ATO) treatment in galectin-3-positive breast cancer cells (MDA-MB-231 and MCF-7), although ATO treatment up-regulated galectin-3 expression. Knockdown of galectin-3 in MDA-MB-231 cells sensitized them to killing by ATO. These findings support a possible role for galectin-3 as a marker for triple-negative breast cancer progression and as a therapeutic target in combination with ATO treatment, although the mechanisms that underlie this synergy require further investigation.http://europepmc.org/articles/PMC4177814?pdf=render |
| spellingShingle | Hao Zhang Minna Luo Xi Liang Dan Wang Xin Gu Chao Duan Huizi Gu Guanglei Chen Xinhan Zhao Zuowei Zhao Caigang Liu Galectin-3 as a marker and potential therapeutic target in breast cancer. PLoS ONE |
| title | Galectin-3 as a marker and potential therapeutic target in breast cancer. |
| title_full | Galectin-3 as a marker and potential therapeutic target in breast cancer. |
| title_fullStr | Galectin-3 as a marker and potential therapeutic target in breast cancer. |
| title_full_unstemmed | Galectin-3 as a marker and potential therapeutic target in breast cancer. |
| title_short | Galectin-3 as a marker and potential therapeutic target in breast cancer. |
| title_sort | galectin 3 as a marker and potential therapeutic target in breast cancer |
| url | http://europepmc.org/articles/PMC4177814?pdf=render |
| work_keys_str_mv | AT haozhang galectin3asamarkerandpotentialtherapeutictargetinbreastcancer AT minnaluo galectin3asamarkerandpotentialtherapeutictargetinbreastcancer AT xiliang galectin3asamarkerandpotentialtherapeutictargetinbreastcancer AT danwang galectin3asamarkerandpotentialtherapeutictargetinbreastcancer AT xingu galectin3asamarkerandpotentialtherapeutictargetinbreastcancer AT chaoduan galectin3asamarkerandpotentialtherapeutictargetinbreastcancer AT huizigu galectin3asamarkerandpotentialtherapeutictargetinbreastcancer AT guangleichen galectin3asamarkerandpotentialtherapeutictargetinbreastcancer AT xinhanzhao galectin3asamarkerandpotentialtherapeutictargetinbreastcancer AT zuoweizhao galectin3asamarkerandpotentialtherapeutictargetinbreastcancer AT caigangliu galectin3asamarkerandpotentialtherapeutictargetinbreastcancer |